Skip to main content
padlock icon - secure page this page is secure

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia

Buy Article:

$52.00 + tax (Refund Policy)

No Abstract.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Institute of Haematology and Medical Oncology ‘‘L. and A. Seràgnoli’’, University of Bologna, Bologna, Italy 2: Department of Haematology, S. Salvatore Hospital, Pesaro, Italy

Publication date: April 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more